Cygnus Biosciences Co. Ltd. (Sina Biotech (Beijing) Co. Ltd.)

Company Overview

Cygnus Biosciences Co. Ltd. is developing and commercializing gene sequencing technology for clinical diagnostics applications.

In 2017, Cygnus licensed fluorogenic sequencing technology from Peking University. The platform combines long reads with pyrosequencing and uses fluorescence-based detection.

The technology is particularly well suited to liquid biopsy applications, including fetal genetic mutation detection in maternal blood and rare mutation identification in ctDNA.

The main improvements that Cygnus (and its partner the University of Peking) have made to previous fluorogenic sequencing include better sequencing chemistry (by using a novel fluorophore known as Tokyo Green with a higher signal to noise ratio) and new ways to correct errors (error code correction technology).

Company's Business Segments

• Gene Sequencing Technology : This technology enables the company to develop an open gene sequencing platform to provide core equipment for life science research and genetic diagnosis, as well as more accurate, simple, and fast solutions for tumors, microorganisms, reproductive health, the environment, and food safety.